|本期目录/Table of Contents|

[1]张,维,吴毓敏,等.社区老年非瓣膜性心房颤动患者的抗凝治疗现状[J].国际心血管病杂志,2016,03:187-189.
　ZHANG Wei,WU Yumin,LIU Qianjun,et al.Current status of anticoagulant therapy in elderly patients with non-valvular atrial fibrillation in community[J].International Journal of Cardiovascular Disease,2016,03:187-189.
点击复制

社区老年非瓣膜性心房颤动患者的抗凝治疗现状(PDF)

《国际心血管病杂志》[ISSN:1006-6977/CN:61-1281/TN]

期数:
2016年03期
页码:
187-189
栏目:
临床研究
出版日期:
2016-05-20

文章信息/Info

Title:
Current status of anticoagulant therapy in elderly patients with non-valvular atrial fibrillation in community
作者:
张; 维; 吴毓敏; 刘千军; 韩维嘉; 郭新贵
200040 上海复旦大学附属华东医院心血管内科
Author(s):
ZHANG Wei;  WU Yumin;  LIU Qianjun;  HAN Weijia;  GUO Xingui.
Department of Cardiology, Affiliated Huadong Hospital of Fudan University, Shanghai 200040, China.
关键词:
心房颤动; 老年人; 抗凝; CHADS2评分
Keywords:
Atrial fibrillation;  Elderly;  Anticoagulation;  CHADS2 score
分类号:
-
DOI:
10.3969/j.issn.1673-6583.2016.03.016
文献标识码:
-
摘要:
目的:探讨社区老年非瓣膜性心房颤动(房颤)患者抗凝治疗现状。方法:采用整群抽样方法,抽取上海市长宁区3个社区中年龄≥65岁的常住居民,入选通过心电图或24h动态心电图及心脏超声检查确诊为非瓣膜性房颤的患者(n=218),对所有患者进行统一问卷调查,包括基本情况、疾病史以及用药情况,并计算CHADS2评分。结果:入选患者中,卒中高危患者(CHADS2评分≥2)有167例,实际接受抗凝治疗的仅23例(13.8%)。对未抗凝治疗原因分析显示,医生未实施抗凝治疗高达63.2%,是抗凝治疗率低的主要原
Abstract:
Objective:To investigate the current status of anticoagulant therapy in elderly patients with non-valvular atrial fibrillation in community.Methods:A random cluster sampling survey was carried out to investigate the elderly(≥ 65 years)living in three comm

参考文献/References

[1] Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham study[J]. Stroke, 1991,22(8):983-988.
[2] 胡大一,孙艺红.周自强,等.中国人非瓣膜性心房颤动脑卒中危险因素的病例对照研究[J].中华内科杂志,2003,42(3):157-161.
[3] Lau DH, Kalman J, Sanders P, et al. Management of recent-onset sustained atrial fibrillation: pharmacologic and nonpharmacologic strategies[J]. Clin Ther, 2014,36(9)1151-1159.
[4] 顾剑云,陈治松,徐文俊. 上海部分地区非瓣膜性心房颤动患者使用华法林抗凝治疗现状调查[J]. 国际心血管病杂志,2015,42(4):288-290.
[5] Camm AJ,Lip GY,De Caterina R,et al.2012 focused update of the ESC Guidelines for the management of atrial fibrillation:an update of the 2010 ESC Guidelines for the management of atrial fibrillation.Developed with the special contribution of the European Heart Rhythm Association[J].Eur Heart J,2012,33(21):2719-2747.
[6] Van Staa TP, Setakis E, Di Tanna GL, et al. A comparison of risk stratification schemes for stroke in 79,884 atrial fibrillation patients in generalpractice[J]. J Thromb Haemost, 2011, 9(1):39-48.
[7] 张 超,刘 旭.解读欧洲心脏病协会首次独立提出的心房颤动指南[J].国际心血管病杂志,2010,37(6):383-384.
[8] 黄 煜.低强度华法林抗凝治疗脑卒中风险房颤患者的临床研究[J].当代医学,2011,17(9):139-140.
[9] 孙艺红,胡大一.非瓣膜病心房颤动患者全球抗凝注册研究——中国亚组基线数据分析[J]. 中华心血管病杂志,2014,42(10):846-850.
[10] Rahman F, Kwan GF, Benjamin EJ. Global epidemiology of atrial fibrillation[J].Nat Rev Cardiol,2014,11(11):639-654.
[11] Kneeland PP,Fang MC.Current issues inpatient adherence and persistence:focus on anticoagulants for the treatment and prevention of thromboembolism [J].Patient Prefer Adherence,2010,4(1):51-60.
[12] Lydie-EdwigeBiye,葛卫红,于 锋,等. 房颤患者规范化抗凝治疗现状调研[J].药学与临床研究,2011,19(4):348-351.
[13] Lip GY,Kamath S,Jafri M,et al.Ethnic differences in patient perceptions of atrial fibrillation and anticoagulation therapy:the West Birmingham Atrial Fibrillation Project[J].Stroke,2002,33(1):238-242.
[14] Razouki Z, Ozonoff A, Zhao S, et al. Pathways to poor anticoagulation control[J].J Thromb Haemost,2014,12(5): 628-634.

备注/Memo

备注/Memo:
通信作者:郭新贵,Email:guoxinguiemail@126.com
更新日期/Last Update: 2016-05-20